tirzepatide cardiovascular outcomes Real-World of Obesity Treatment With Versus Semaglutide in Non-Diabetic Adults In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF Subgroup analysis of cardiovascular adverse

#glp1 | Dr

GSH-assisted lipotransfer is a promising therapeutic strategy for future clinical application

M.KotiadisV

On breastfeeding, both the SmPC and the MHRA agree that Wegovy shouldnt be used

#Pharmacovigilance #PatientSafety #ClinicalPharmacy #DrugSafety #HealthcareAwareness #ADRReporting #Semaglutide #GLP1 #DiabetesCare #WeightManagement #Pharma #HealthcareProfessionals #PvPI #MedicationSafety Semaglutide Adverse Reactions and Reporting **Adverse Drug Reactions Awareness: Semaglutide (GLP-1 Receptor Agonist)** Semaglutide has transformed the management of **Type 2 Diabetes** and **chronic weight management**, with added cardiovascular benefits

Linaclotide and related peptides improve bowel habits and abdominal pain in IBS-C and chronic constipation